Edition:
United States

Endo International PLC (ENDP.OQ)

ENDP.OQ on NASDAQ Stock Exchange Global Select Market

12.38USD
21 Jul 2017
Change (% chg)

$0.06 (+0.49%)
Prev Close
$12.32
Open
$12.37
Day's High
$12.46
Day's Low
$12.21
Volume
841,585
Avg. Vol
1,672,827
52-wk High
$24.91
52-wk Low
$9.70

Latest Key Developments (Source: Significant Developments)

Endo to restructure manufacturing network
Friday, 21 Jul 2017 08:30am EDT 

July 21 (Reuters) - Endo International Plc ::Endo to restructure manufacturing network.Endo to restructure manufacturing network.Endo International Plc - closure of facilities is expected to take place over next 12 to 18 months.Endo International Plc - ‍restructuring actions are expected to reduce endo's workforce by approximately 875 positions​.Says ‍Huntsville location has been impacted by declining volumes of commoditized products​.Endo International Plc - ‍restructuring actions to result in pre-tax restructuring charges of approximately $325 million​.Endo International Plc - remaining estimated non-cash charges consist primarily of accelerated depreciation of approximately $165 million.Endo International Plc - Endo expects to realize approximately $55 million to $65 million in annual net run rate pre-tax cost savings by Q4 of 2018.Endo International - ‍expects to realize approximately $55 million to $65 million in annual net run rate pre-tax cost savings by Q4 of 2018 from restructuring​.Endo International Plc - ‍company will be ceasing operations and closing its manufacturing and distribution facilities in Huntsville, Alabama​.  Full Article

Endo decides to voluntarily remove OPANA ER from market
Thursday, 6 Jul 2017 12:15pm EDT 

July 6 (Reuters) - Endo International Plc : :Endo provides update on OPANA® ER.Endo International-After consideration, consultation with U.S. FDA following withdrawal request, company has decided to voluntarily remove OPANA ER from market.Endo International Plc - Expects to incur a pre-tax impairment charge of approximately $20 million in Q2 of 2017.Endo International Plc - ‍endo plans to work with FDA to coordinate orderly removal of OPANA ER​.Endo International Plc - Continues to believe in safety, efficacy, and favorable benefit-risk profile of OPANA ER.  Full Article

Endo divests Grupo Farmacéutico SOMAR in $124 mln deal
Wednesday, 5 Jul 2017 07:30am EDT 

July 5 (Reuters) - Endo International Plc :Endo announces divestiture of grupo farmacéutico somar.Endo announces divestiture of grupo farmacéutico somar.Endo international plc - deal for ‍approximately $124 million​.Says ‍to sell mexico city based grupo farmacéutico somar to advent international for approximately $124 million​.Endo international plc - deal for approximately $124 million.Endo international plc - endo intends to classify somar assets and liabilities as held-for-sale in second-quarter 2017.Endo international plc - expects to record estimated pre-tax impairment charge of approximately $100 million.Endo international- will finalize analysis and record any required impairment charges in connection with second-quarter 2017 financial reporting close​.Endo international - will finalize analysis,record required impairment charges in connection with its second-quarter 2017 financial reporting close.  Full Article

Endo completes divestiture of Litha Healthcare Group
Monday, 3 Jul 2017 01:45pm EDT 

July 3 (Reuters) - Endo International Plc :Endo completes divestiture of Litha Healthcare Group.Endo International Plc - during q4 of 2016, endo recorded pre-tax impairment charges of about $150 million in order to write-down litha's net assets.  Full Article

Endo says reviewing FDA's request to withdraw Opana ER from market
Thursday, 8 Jun 2017 05:47pm EDT 

June 8 (Reuters) - Endo International Plc ::Endo response to june 8, 2017 FDA meeting related to opana® er.Endo international plc- "endo is reviewing request and is evaluating full range of potential options as we determine appropriate path forward".Endo - fda's request to withdraw opana er from market does not indicate uncertainty with product's safety or efficacy when taken as prescribed.  Full Article

Endo International reports entry of significant case management order in Mesh multidistrict litigation​
Wednesday, 7 Jun 2017 05:13pm EDT 

June 7 (Reuters) - Endo International Plc ::Endo International Plc - ‍announces entry of significant case management order in mesh multidistrict litigation​.  Full Article

Veloxis Pharmaceuticals A/S, Endo Ventures enter deal to commercialize Envarsus XR in Canada
Tuesday, 6 Jun 2017 02:59pm EDT 

June 6 (Reuters) - Veloxis Pharmaceuticals A/S ::Veloxis Pharmaceuticals A/S and Endo Ventures Limited jointly announce agreement for Paladin Labs Inc. To commercialize Envarsus XR® in Canada.Initial term of agreement is 15 years from effective date of agreement.Under terms of deal, co will get up-front payment and veloxis will supply envarsus xr at a pre-specified transfer price​.  Full Article

Endo reports Q1 GAAP loss per share $0.74
Tuesday, 9 May 2017 06:30am EDT 

May 9 (Reuters) - Endo International PLC : :Endo reports first-quarter 2017 financial results.Q1 adjusted earnings per share $1.23 from continuing operations.Q1 GAAP loss per share $0.74 from continuing operations.Q1 revenue $1.038 billion versus I/B/E/S view $1.02 billion.Q1 earnings per share view $1.10 -- Thomson Reuters I/B/E/S.Endo International PLC sees 2017 total revenues to be between $3.45 billion to $3.60 billion.Endo International PLC sees 2017 reported diluted gaap loss per share from continuing operations to be between $0.80 and $0.50.Endo International PLC sees 2017 adjusted diluted eps from continuing operations to be between $3.45 to $3.75.Endo International PLC - divestiture of its south african subsidiary, Litha Healthcare Group, to Acino Pharma AG is expected to close in Q2 of 2017.Endo International PLC - during first-quarter 2017, company recorded total combined pre-tax, non-cash impairment charges of $204 million.FY2017 earnings per share view $3.61 -- Thomson Reuters I/B/E/S.FY2017 revenue view $3.54 billion -- Thomson Reuters I/B/E/S.Endo International PLC - in April 2017, endo refinanced its $3.7 billion existing credit agreement.Endo International - recorded Q1 2017 restructuring cash charges of $15 million related to its restructuring program.  Full Article

Endo International priced $300 million aggregate amount of 5.875% senior secured notes
Wednesday, 12 Apr 2017 09:36pm EDT 

Endo International Plc : Endo International Plc announces pricing of private offering of senior secured notes .Endo International-cos subsidiaries, priced $300 million aggregate amount of 5.875% senior secured notes due 2024 at an issue price of $1000 per $1000 principal amount.  Full Article

Endo International priced $300 million aggregate amount of 5.875% senior secured notes
Wednesday, 12 Apr 2017 07:20pm EDT 

Endo International Plc : Endo International Plc announces pricing of private offering of senior secured notes .Endo International-cos subsidiaries, priced $300 million aggregate amount of 5.875% senior secured notes due 2024 at an issue price of $1000 per $1000 principal amount.  Full Article

Photo

U.S. asks drug maker Endo to withdraw opioid amid abuse crisis

WASHINGTON As the United States battles a growing opioid abuse crisis, the Food and Drug Administration on Thursday asked Endo International Plc to withdraw from the market its long-lasting opioid painkiller, Opana ER, sending Endo's shares down more than 12 percent.